Glaukos price target raised to $77 from $65 at Stifel

Stifel analyst Thomas Stephan raised the firm’s price target on Glaukos (GKOS) to $77 from $65 and keeps a Buy rating on the shares. There are “clear indications” from the likes of UnitedHealth (UNH) and Humana (HUM) that outpatient surgery volumes have accelerated of late, says the firm, which believes cataract surgery “likely falls under this umbrella” and thinks should mean MIGS trends are also solid. The setup for the upcoming print is “favorable” as both Q2 and FY23 estimates “appear conservative,” the analyst added.